Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation

Blood

Volumn 102, Issue 3, 2003, Pages 1087-1096

  De Franceschi, Lucia ^a   Baron, Antonella ^b   Scarpa, Aldo ^b   Adrie, Christophe ^b   Janin, Anne ^b   Barbi, Stefano ^b   Kister, Jean ^b   Rouyer Fessard, Philippe ^b   Corrocher, Roberto ^b   Leboulch, Philippe ^b   Beuzard, Yves ^b  

^a Policlinico GB Rossi   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GENE PRODUCT; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 1BETA; HEMOGLOBIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; METHEMOGLOBIN; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACE GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FGF7 GENE; GENE; GENE EXPRESSION PROFILING; GENE INDUCTION; HISTOPATHOLOGY; HSP86 1 GENE; HSPCB GENE; HYPOXIA; INFLAMMATION; LEUKOCYTE COUNT; LUNG INJURY; LUNG LAVAGE; MICROCIRCULATION; MOUSE; NEUTROPHIL; NFE2L2 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REOXYGENATION; SICKLE CELL ANEMIA; TRANSGENIC MOUSE;

EID: 0043245821     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2135     Document Type: Article

References (59)

1. Nagel R, Platt O. General pathophysiology of sickle cell anemia. In: Steinberg M, Forget B, Higgs D, Nagel R, eds. Disorders of Hemoglobin. Cambridge, MA: Cambridge University Press; 2001:494-526.
2. Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood. 1999;94:1555-1560.
3. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;79:2154-2163.
4. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340:1021-1030.
5. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998;101:1899-1904.
6. Trudel M, Saadane N, Garel MC, et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J. 1991;10:3157-3165.
7. Trudel M, De Paepe ME, Chretien N, et al. Sickle cell disease of transgenic SAD mice. Blood. 1994;84:3189-3197.
8. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294: 2368-2371.
9. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997; 278:876-878.
10. Fabry ME, Suzuka SM, Weinberg RS, et al. Second generation knockout sickle mice: the effect of HbF. Blood. 2001;97:410-418.
11. Chang JC, Lu R, Lin C, et al. Transgenic knock-out mice exclusively expressing human hemoglobin S after transfer of a 240-kb betas-globin yeast artificial chromosome: a mouse model of sickle cell anemia. Proc Natl Acad Sci U S A. 1998;95: 14886-14890.
12. Fabry ME, Costantini F, Pachnis A, et al. High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci U S A. 1992;89:12155-12159.
13. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 2000;96:314-320.
14. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420.
15. Hillery C, Holzman S, Franciosi J, et al. Changes in hsp90-eNOS interactions following hypoxia-induced acute lung injury in a murine model of sickle cell disease [abstract]. Blood. 2002;100:29.
16. Martinez-Ruiz R, Montero-Huerta P, Hromi J, Head CA. Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model. Anesthesiology. 2001;94:1113-1118.
17. Belcher J, Marker P, Hebbel R, Vercellotti G. Inflammatory response in transgenic mouse models of human sickle cell anemia [abstract]. Blood. 2000;90:2574.
18. Weiner D, Hibberd P, Betit P, Botelho C, Cooper A, Brugnara C. Inhaled nitric oxide for treatment of vaso-occlusive crisis of sickle cell disease [abstract]. Blood. 2002;100:27.
19. Roberts JD Jr, Fineman JR, Morin FC 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336:605-610.
20. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology. 1997;87:988-990.
21. Fox-Robichaud A, Payne D, Hasan SU, et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest. 1998;101:2497-2505.
22. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991;83:2038-2047.
23. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65: 1-21.
24. Granger DN. Ischemia-reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation. 1999;6:167-178.
25. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
26. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993; 328:399-405.
27. Lopez BL, Barnett J, Ballas SK, Christopher TA, Davis-Moon L, Ma X. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Acad Emerg Med. 1996;3:1098-1103.
28. Qureshe M, Swerdlow P, Girgis R. Decreased exhaled nitric oxide (NO) in patients with sickle cell disease [abstract]. Blood. 2000;90:2571.
29. Zheng S, Zhang WY, Zhu LW, Lin K, Sun B. Surfactant and inhaled nitric oxide in rats alleviate acute lung injury induced by intestinal ischemia and reperfusion. J Pediatr Surg. 2001;36:980-984.
30. Warnecke G, Struber M, Fraud S, Hohlfeld JM, Haverich A. Combined exogenous surfactant and inhaled nitric oxide therapy for lung ischemia-reperfusion injury in minipigs. Transplantation. 2001;71:1238-1244.
31. Koh Y, Kang JL, Park W, et al. Inhaled nitric oxide down-regulates intrapulmonary nitric oxide production in lipopolysaccharide-induced acute lung injury. Crit Care Med. 2001;29:1169-1174.
32. Schutte H, Witzenrath M, Mayer K, Rosseau S, Seeger W, Grimminger F. Short-term "preconditioning" with inhaled nitric oxide protects rabbit lungs against ischemia-reperfusion injury. Transplantation. 2001;72:1363-1370.
33. Thabut G, Brugiere O, Leseche G, et al. Preventive effect of inhaled nitric oxide and pentoxifylline on ischemia/reperfusion injury after lung transplantation. Transplantation. 2001;71:1295-1300.
34. Gladwin MT, Schechter AN, Shelhamer JH, et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest. 1999;104:937-945.
35. Cannon RO 3rd, Schechter AN, Panza JA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest. 2001;108:279-287.
36. De Franceschi L, Brugnara C, Rouyer-Fessard P, Jouault H, Beuzard Y. Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. Blood. 1999;94:4307-4313.
37. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
38. Smid-Koopman E, Blok LJ, Chadha-Ajwani S, Helmerhorst TJ, Brinkmann AO, Huikeshoven FJ. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer. 2000;83:246-251.
39. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene. 2001;20: 7437-7446.
40. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene. 2002;21:4587-4594.
41. Rajeevan MS, Ranamukhaarachchi DG, Vernon SD, Unger ER. Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. Methods. 2001;25: 443-451.
42. Sheppard D, Roger S. Mitchell lecture. Uses of expression microarrays in studies of pulmonary fibrosis, asthma, acute lung injury, and emphysema. Chest. 2002;121:21S-25S.
43. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30: e15.
44. Huaux F, Lardot C, Arras M, et al. Lung fibrosis induced by silica particles in NMRI mice is associated with an upregulation of the p40 subunit of interleukin- 12 and Th-2 manifestations. Am J Respir Cell Mol Biol. 1999;20:561-572.
45. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. 1999;26: 74-84.
46. Dale EC, Yang X, Moore SK, Shyamala G. Murine 86-kDa heat shock protein gene and promoter. Cell Stress Chaperones. 1997;2:87-93.
47. Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci U S A. 1999;96:12731-12736.
48. Takahashi K, Kubo T, Goomer RS, et al. Analysis of heat shock proteins and cytokines expressed during early stages of osteoarthritis in a mouse model. Osteoarthritis Cartilage. 1997;5:321-329.
49. Kelly KJ, Baird NR, Greene AL. Induction of stress response proteins and experimental renal ischemia/reperfusion. Kidney Int. 2001;59:1798-1802.
50. van Suylen RJ, Aartsen WM, Smits JF, Daemen MJ. Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia. Am J Respir Crit Care Med. 2001;163:1241-1245.
51. Tamaru N, Watanabe K, Yoshida M, Reitz-Vick DM, Townsend L, Glover J. Angiotensin-converting enzyme activity by canine pulmonary microvascular and central pulmonary artery endothelial cells exposed to hypoxia. Lung. 2000;178:249-255.
52. Welsh DA, Guery BP, Deboisbianc BP, et al. Keratinocyte growth factor attenuates hydrostatic pulmonary edema in an isolated, perfused rat lung model. Am J Physiol Heart Circ Physiol. 2001;280:H1311-1317.
53. Das M, Dempsey EC, Bouchey D, Reyland ME, Stenmark KR. Chronic hypoxia induces exaggerated growth responses in pulmonary artery adventitial fibroblasts: potential contribution of specific protein kinase c isozymes. Am J Respir Cell Mol Biol. 2000;22:15-25.
54. Frevert CW, Farone A, Danaee H, Paulauskis JD, Kobzik L. Functional characterization of rat chemokine macrophage inflammatory protein-2. Inflammation. 1995;19:133-142.
55. Shanley TP, Schmal H, Warner RL, Schmid E, Friedl HP, Ward PA. Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury, J Immunol. 1997;158:3439-3448.
56. Smith RE, Strieter RM, Phan SH, Lukacs N, Kunkel SL. TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J Leukoc Biol. 1998;64:528-536.
57. Warren JS, Yabroff KR, Remick DG, et al. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest. 1989;84:1873-1882.
58. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 2002;99:1103-1108.
59. de Franceschi L, Baron A, Scarpa A, Adrie C, Rouyer-Fessard P, Beuzard Y. Inhaled nitric oxide has a protective effect in hypoxic transgenic sickle cell mice (SAD): evidences of modulation of ischemic lung injury [abstract]. Blood. 2001; 98(11)(suppl 1):3125.